Nikulski Financial Inc. Has $781,000 Position in Amgen Inc. (NASDAQ:AMGN)

Nikulski Financial Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 35.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,710 shares of the medical research company’s stock after buying an additional 713 shares during the quarter. Nikulski Financial Inc.’s holdings in Amgen were worth $781,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock valued at $13,178,910,000 after purchasing an additional 165,636 shares during the period. Morgan Stanley lifted its stake in shares of Amgen by 12.9% in the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Amgen by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock valued at $2,132,778,000 after purchasing an additional 94,565 shares during the period. Moneta Group Investment Advisors LLC lifted its stake in shares of Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock valued at $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Amgen by 3.8% in the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price objective on Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. The Goldman Sachs Group boosted their price objective on Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $329.00 target price on shares of Amgen in a research report on Wednesday, April 3rd. TD Cowen dropped their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Stock Performance

Shares of AMGN traded up $6.18 on Friday, reaching $268.93. 3,380,330 shares of the company’s stock traded hands, compared to its average volume of 2,077,465. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The stock has a market cap of $144.25 billion, a PE ratio of 21.53, a PEG ratio of 2.50 and a beta of 0.58. The stock’s 50 day simple moving average is $276.90 and its two-hundred day simple moving average is $281.40. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s revenue was up 19.8% on a year-over-year basis. During the same period last year, the business posted $4.09 earnings per share. On average, analysts forecast that Amgen Inc. will post 19.45 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.